Malignant Peripheral Nerve Sheath Tumors (MPNSTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are aggressive soft tissue tumors that primarily originate from the peripheral nerves. They demonstrate variable differentiation towards the cellular components of the nerve sheath, such as Schwann cells, fibroblasts, or perineurial cells. MPNSTs are common in adults with no gender bias but tend to occur at a younger mean age in patients with neurofibromatosis type 1 (NF1). The tumors are most frequently found in the extremities, particularly proximally, followed by the trunk, head, and neck. The sciatic nerve is the most commonly involved major nerve trunk. Clinical presentation includes a painful or rapidly growing mass and associated neurologic deficits. Approximately half of the MPNSTs arise in the context of NF1 syndrome, often associated with pre-existing plexiform neurofibromas. The lifetime risk of developing MPNST in NF1 patients is 8-13%. An important symptom is developing new, worsening, or persistent pain in a neurofibroma in an NF1 patient. Patients present with a rapidly growing mass that may be painful or cause local neurological symptoms such as weakness or paresthesia. At presentation, the mass is commonly larger than 5 cm, and up to 50% of patients present with metastatic disease, usually to the lung. In cases of localized disease, surgical extirpation with clear margins is the treatment of choice.
·
The estimated incidence of malignant
Peripheral Nerve Sheath Tumors in the USA is 1.46 per 1,000,000.
Thelansis’s “Malignant Peripheral
Nerve Sheath Tumors (MPNSTs) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2022 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Malignant
Peripheral Nerve Sheath Tumors (MPNSTs) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Malignant Peripheral Nerve Sheath Tumors (MPNSTs) across 8 MM market from
the centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Malignant Peripheral Nerve Sheath
Tumors (MPNSTs) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment